Themis preps first clinical test of oncolytic viral approach with €40M round

With its infectious disease programs well-funded, Themis will use its series D to explore cancer indications

As Themis continues to develop vaccines using its measles viral vectors to treat infectious diseases, the Austrian biotech also hopes to use its new €40 million ($44.3 million) series D round to conduct its first clinical study applying its platform in immuno-oncology.

“Almost all cancer cells overexpress a specific receptor, CD46, and measles happens to meet

Read the full 557 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE